Image-Guided Radiation Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (4D RT, LINAC, MRI-guided radiotherapy, Portal CT Imaging), By Procedure (IMRT, Stereotactic, Particle), By Application (Neck, Prostate, Breast cancer), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.02 Billion
CAGR (2026-2031)	5.45%
Fastest Growing Segment	MRI-guided Radiotherapy
Largest Market	North America
Market Size (2031)	USD 2.78 Billion

Market Overview

The Global Image-Guided Radiation Therapy Market will grow from USD 2.02 Billion in 2025 to USD 2.78 Billion by 2031 at a 5.45% CAGR. Image-Guided Radiation Therapy (IGRT) is a precise form of radiation treatment that incorporates frequent imaging protocols, such as computed tomography or magnetic resonance imaging, during the delivery process to enhance tumor targeting accuracy and spare healthy tissue. The primary drivers fueling market growth include the rising global incidence of cancer and the increasing preference for non-invasive therapies that offer improved safety profiles and treatment efficacy. According to the International Atomic Energy Agency, in 2024, approximately 50 to 70 percent of all cancer patients globally required radiotherapy, highlighting the substantial demand for high-precision technologies that can optimize these essential treatments.

However, the market faces a significant challenge regarding the substantial capital investment required to acquire and install these complex systems. The prohibitive costs associated with equipment procurement, coupled with the expense of specialized infrastructure and ongoing maintenance, create high financial barriers that restrict adoption rates, particularly in healthcare facilities within low- and middle-income regions.

Key Market Drivers

Rising global incidence of cancer cases acts as the primary catalyst for the Image-Guided Radiation Therapy market, necessitating scalable treatment solutions to manage growing patient volumes. As cancer burdens escalate, healthcare providers must adopt high-throughput systems that deliver effective localized control while minimizing side effects. This urgency is underscored by data highlighting the disease's scale; according to the World Health Organization's International Agency for Research on Cancer, February 2024, in the 'Global Cancer Burden' press release, there were an estimated 20 million new cancer cases globally in 2022. This increasing caseload directly translates into heightened procurement of radiation therapy equipment as hospitals expand oncology capabilities to meet the critical care needs of a larger patient population.

Simultaneously, rapid technological advancements, particularly the integration of artificial intelligence, are driving market expansion by revolutionizing treatment delivery. Modern IGRT systems now leverage adaptive algorithms to adjust radiation beams in real-time, significantly enhancing targeting precision. This shift towards adaptive platforms is reflected in commercial performance; according to Accuray Incorporated, August 2024, in the 'Fourth Quarter and Fiscal 2024 Financial Results', the company reported gross orders of $342.1 million, indicating robust demand for precision technologies. The sector's financial scale is further illustrated by market leaders; according to Siemens Healthineers, in 2024, the Varian segment recorded a total revenue of $4.14 billion, driven by the sustained adoption of advanced radiotherapy solutions.

Download Free Sample Report

Key Market Challenges

The substantial capital investment required to acquire and install Image-Guided Radiation Therapy (IGRT) systems acts as a significant restraint on the market's global expansion. These complex treatment platforms necessitate not only the purchase of expensive hardware but also heavy expenditure on specialized infrastructure, such as radiation-shielded rooms, alongside strict continuous maintenance requirements. This financial burden creates a high barrier to entry that restricts the ability of healthcare facilities, particularly in resource-limited settings, to procure necessary equipment, thereby effectively capping the market’s potential customer base and slowing adoption rates.

This economic obstacle results in a severe accessibility gap that directly impedes market penetration in developing regions where the clinical need is often highest. According to the Global Coalition for Radiotherapy, in 2024, approximately 58 countries globally possessed no radiotherapy services whatsoever, a deficit driven primarily by the inability of local healthcare systems to fund the initial capitalization and operational costs of these technologies. This absence of infrastructure in such a large number of nations prevents manufacturers from unlocking significant revenue streams in emerging markets, limiting the overall growth trajectory of the global industry.

Key Market Trends

The Development of Biologically Guided Radiation Therapy Platforms represents a transformative shift in the market, moving beyond anatomical imaging to utilize tumor biology for real-time targeting. Unlike conventional systems that rely solely on structural changes, these platforms detect positron emission tomography signals emitted directly by the tumor, allowing for the precise treatment of multiple metastatic sites during a single session. This advancement addresses the critical need for managing late-stage cancers where traditional focal therapies fall short. The rapid expansion of this technology is underscored by regulatory progress; according to RefleXion Medical, January 2025, in the 'RefleXion Launches Pivotal Study' press release, updated reimbursement codes will now allow approximately 400,000 additional patients to access SCINTIX therapy, highlighting the substantial clinical integration of biologically driven workflows.

Simultaneously, the Incorporation of Cloud-Based Treatment Planning and Data Analytics is streamlining complex oncology operations through centralized digital ecosystems. Healthcare providers are increasingly transitioning from isolated, on-premise workstations to interconnected software solutions that facilitate remote plan review, multi-site data sharing, and enhanced operational efficiency. This digital consolidation allows clinics to manage expanding patient loads effectively without proportional increases in physical infrastructure. The commercial viability of this trend is evident in recent financial performance; according to Elekta, May 2025, in the 'Year-end report May 2024/25', the company reported double-digit growth in its software business, a key factor contributing to an adjusted EBIT margin of 16.3 percent, signaling a decisive industry move towards software-centric care delivery models.

Segmental Insights

The MRI-guided radiotherapy segment is currently recognized as the fastest-growing category within the global image-guided radiation therapy market. This rapid expansion is largely attributed to the modality providing enhanced soft-tissue visualization relative to conventional computed tomography methods. Such clarity enables clinicians to monitor tumor position in real-time and adapt treatment plans immediately, effectively limiting radiation exposure to surrounding healthy organs. Furthermore, continued product clearances by the US FDA for integrated MRI-linear accelerator systems have bolstered market confidence, thereby accelerating the clinical implementation of these adaptive therapeutic solutions across major healthcare facilities.

Regional Insights

North America maintains a dominant position in the global Image-Guided Radiation Therapy market, driven by established healthcare infrastructure and a high prevalence of oncological disorders. The region benefits from the concentrated presence of major medical technology manufacturers, facilitating the rapid adoption of advanced therapeutic systems. Market expansion is further supported by favorable regulatory frameworks managed by the U.S. Food and Drug Administration, which streamline product approvals. Additionally, comprehensive reimbursement policies from the Centers for Medicare & Medicaid Services facilitate broader patient access to radiation treatments, reinforcing the region's leadership.

Recent Developments

• In November 2024, Varian, a Siemens Healthineers company, signed a strategic framework agreement with Institut Curie to accelerate research and innovation in the field of radiotherapy. This three-year collaboration focuses on combining the clinical expertise of the cancer center with the company's technological capabilities to develop more precise and personalized treatment options. The partners aim to initiate ambitious research projects that utilize next-generation equipment and software to optimize the patient care pathway. By formalizing this joint development strategy, the alliance seeks to expedite the creation and market introduction of breakthrough technologies that enhance the efficacy of image-guided treatments.
• In September 2024, GE HealthCare showcased significant innovations in radiation oncology at the American Society for Radiation Oncology Annual Meeting, highlighting its Intelligent Radiation Therapy (iRT) platform. The company introduced updates that leverage artificial intelligence to enhance interoperability between multi-vendor systems, aiming to streamline the complex workflow from simulation to treatment. The presentation also featured the Revolution RT, a wide-bore computed tomography solution designed to increase simulation accuracy for precise dose delivery. Furthermore, the integration of advanced software tools for automated contouring and image fusion was demonstrated, intended to reduce the time between diagnosis and the commencement of radiation therapy.
• In August 2024, Accuray Incorporated received the CE Mark for its Accuray Helix system, a computed tomography-guided helical radiotherapy platform specifically engineered for healthcare providers in emerging markets. The company developed this system to deliver high-performance and high-throughput treatments, addressing the growing demand for accessible cancer care in non-urban regions. The platform combines advanced automation with precise helical delivery to treat a broad range of cancer types, including breast and head and neck malignancies. This regulatory clearance allows the company to expand its portfolio and support clinics in managing heavy patient loads while maintaining treatment accuracy and efficiency.
• In May 2024, Elekta announced the launch of Evo, a versatile CT-Linac system designed to advance the capabilities of image-guided radiation therapy through artificial intelligence. This new platform features high-definition imaging technology that supports both offline and online adaptive radiotherapy, allowing clinicians to adjust treatment plans based on anatomical changes. The system incorporates anatomy-specific algorithms to improve the visualization of target areas and organs at risk, thereby enhancing the precision of radiation delivery. By enabling a more personalized approach to cancer treatment, the technology aims to reduce uncertainties during therapy and improve overall patient outcomes.

Key Market Players

• Siemens Healthineers AG
• ViewRay, Inc.
• Varian Medical Systems, Inc.
• Toshiba Corporation
• GE HealthCare Technologies, Inc.
• Accuray Inc.
• Becton, Dickinson, and Company
• Vision RT Ltd.

By Product	By Procedure	By Application	By Region
4D RT LINAC MRI-guided radiotherapy Portal CT Imaging	IMRT Stereotactic Particle	Neck Prostate Breast cancer	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Image-Guided Radiation Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Image-Guided Radiation Therapy Market, By Product:

• 4D RT
• LINAC
• MRI-guided radiotherapy
• Portal CT Imaging

• Image-Guided Radiation Therapy Market, By Procedure:

• IMRT
• Stereotactic
• Particle

• Image-Guided Radiation Therapy Market, By Application:

• Neck
• Prostate
• Breast cancer

• Image-Guided Radiation Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE